AZ fleshes out positive trial of revitalised lupus drug anifrolumabAfter being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn with new data that suggest Share XAZ fleshes out positive trial of revitalised lupus drug anifrolumabhttps://pharmaphorum.com/news/az-fleshes-out-positive-trial-of-revitalised-lupus-drug-anifrolumab/
GSK must continue to improve R&D, says CEO WalmsleyIt’s been two and a half years since Emma Walmsley took over as CEO of GlaxoSmithKline, and at Share XGSK must continue to improve R&D, says CEO Walmsleyhttps://pharmaphorum.com/news/gsk-must-continue-to-improve-rd-says-ceo-walmsley/
FDA tags F2G’s olorofim as Breakthrough Therapy for fungal infectionsThe US drugs regulator has tagged F2G’s olorofim as a potential Breakthrough Therapy for life-threatening fungal infections, pledging Share XFDA tags F2G’s olorofim as Breakthrough Therapy for fungal infectionshttps://pharmaphorum.com/news/fda-tags-f2gs-olorofilm-as-breakthrough-therapy-for-mould-infections/
AZ preps for US filing of kidney disease anaemia drugAstraZeneca is gearing up for a US filing for its roxadustat, a potential drug for patients with anaemia Share XAZ preps for US filing of kidney disease anaemia drughttps://pharmaphorum.com/news/az-preps-for-us-filing-of-kidney-disease-anaemia-drugs/
Roche joins others in dropping myostatin inhibitor for DMDThe prospects of a new class of Duchenne muscular dystrophy therapies have taken another downturn after Roche abandoned Share XRoche joins others in dropping myostatin inhibitor for DMDhttps://pharmaphorum.com/news/roche-joins-others-in-dropping-myostatin-inhibitor-for-dmd/
Novo Nordisk buys rights to NASH drug from Japan’s UBENovo Nordisk has acquired rights to a preclinical drug that could be used to treat non-alcoholic steatohepatitis (NASH), Share XNovo Nordisk buys rights to NASH drug from Japan’s UBEhttps://pharmaphorum.com/news/novo-nordisk-buys-rights-to-nash-drug-as/
Vifor joins forces with Evotec on kidney disease joint ventureEvotec has teamed up with Swiss pharma company Vifor to create a joint venture that will focus on Share XVifor joins forces with Evotec on kidney disease joint venturehttps://pharmaphorum.com/news/vifor-joins-forces-with-evotec-on-kidney-disease-joint-venture/
Experts concerned over mixed results from Takeda’s dengue vaccineTakeda’s dengue vaccine has met its target of protection against the disease in children – but there are Share XExperts concerned over mixed results from Takeda’s dengue vaccinehttps://pharmaphorum.com/news/experts-concerned-over-mixed-results-from-takedas-dengue-vaccine/
UK startup Ervaxx targets ‘dark matter’ of human genomeAfter two years in stealth mode, London-based biotech Ervaxx has officially launched with $17.5 million in first-round financing Share XUK startup Ervaxx targets ‘dark matter’ of human genomehttps://pharmaphorum.com/news/uk-startup-ervaxx-targets-dark-matter-of-human-genome/
